Meta-analysis confirms no OS benefit from antiangiogenics for NSCLC patients

DENVER – Once again, angiogenesis inhibitors have been examined for benefit against advanced non–small cell lung cancer (NSCLC) and have been found wanting.

Results of a meta-analysis limited to...